Abemaciclib, a selective CDK4/6 inhibitor, has significantly improved outcomes in hormone receptor-positive breast cancer and is being actively explored in tumors characterized by cell cycle dysregulation, including endometrial and ovarian cancers. The gene discussed is CDK4; the disease is ovarian carcinoma.